Google sister company Verily wraps up clinical trial platform acquisition

Listen
Text
  • Small
  • Medium
  • Large

Verily, a subsidiary of Alphabet and Google's sister company, finalized its acquisition of clinical trial management system SignalPath, Verily said Aug. 31. 

By purchasing SignalPath, Verily aims to strengthen its existing clinical trial system, Baseline, which supports clinical trial execution, improved data aggregation and analysis, and flexible study options to accommodate hybrid trials, among other features. 

SignalPath's platform helps research sites improve their costs while reducing the complexities and time associated with trials, according to the news release. 

SignalPath co-founder and CEO Brad Hirsch, MD, will remain part of the company while SignalPath's 100 employees join Verily's clinical research business.

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars